Gynae Onco Questions for MCH OnCosurgery
Q1.) Following are co-factors in HPV oncogenesis except-
a) High parity
c) Co-infection with STDs
Ans: d Age
A number of cofactors have been identified that may contribute to the development of HPV oncogenesis and include smoking, high parity, and coinfection with other sexually transmitted diseases.
Q2 .All of the following statements regarding screening in cervical cancer are true except-
- Screening is recommended to begin at age 21 years
- For 21-29 years, Pap tests are recommended every 3 years alongwith HPV testing because of high prevalence of HPV infection in this age group.
- Women who have had a total hysterectomy for benign conditions may discontinue routine screening
- Women between age 30-65 years, are recommended to have both Pap and HPV testing every 5 years.
For 21-29 years,Pap test is recommended every 3 years.
There is high prevalence of transient, benign HPV infections in women aged younger than 30 years, HPV testing is not recommended for this group.
Q3 Following conditions raise concern of ovarian malignancy except-
a) Complex masses with solid areas
b) Presence of mural nodule
c) Symptomatic masses
d) Unilateral disease.
Ans:d Unilateral disease
Following conditions raise suspicion of possible malignancy-
complex masses with sonographic evidence of solid areas,
thick septations and/or mural nodules,
persistent or enlarging complex masses in premenopausal patients,
complex masses of any size in postmenopausal, masses associated with elevated tumor markers, and finally symptomatic masses (pelvic pain or discomfort, clear vaginal discharge, bladder and/or gastrointestinal effects).
Q4 ) HPV16 and HPV18 are found in what% of cervical cancers?
HPV16 and HPV18 are found in approximately 70% of cervical cancers.
Ref:devita (below fig 74.1)
Q5) Vaginal cancer in women who have history of long term use of pessary, most commonly involves-
- Anterior wall
- Posterior wall
- Lateral fornix
- equal occurrence
Ans:B Posterior wall